Brianna Abbott is a Health Reporter at The Wall Street Journal. She specializes in the treatment and prevention of disease, with a particular focus on oncology, hematology, and immunotherapy, while also exploring themes in alternative medicine and palliative care. Brianna's work has been featured in prominent outlets including MarketWatch, Yahoo Finance, and STAT News, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Brianna Abbott predominantly covers health-related topics, with a focus on government announcements and data-driven insights. Given her interest in citing data and government announcements, she is likely to be responsive to pitches offering expert commentary or analysis based on robust scientific evidence or official statements.
She often addresses timely healthcare issues such as Covid-19, vaccines, cancer treatment, and other respiratory illnesses. Therefore, experts who can provide up-to-date information backed by credible research or those involved in policymaking related to these areas may find success when reaching out to Brianna for coverage opportunities.
Considering her national focus within the United States, experts with insights into U.S.-specific healthcare policies or developments may have an advantage when pitching ideas for articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Reported cases have surged. Doctors and scientists point to how diagnosis and awareness have morphed over time.
By: Brianna Abbott
An early marker for Alzheimer's disease from Florida International University took second place By Brianna Abbott
By: Brianna Abbott, Artur Plawgo
A platelet-stimulating drug may reduce bleeding risk and help patients continue regular doses of their cancer treatment.
A woman's breast tissue undergoes dramatic changes as it ages, creating an environment where cancer cells are more likely to flourish, a new study has found.
A blood pressure drug has the potential to combat one of the most common, difficult-to-treat bacterial infections, according to a new study.
Brianna Abbott is a freelance writer for BioSpace. She is a seasoned healthcare reporter, covering cancer, infectious disease, the business of medicine and more.
By: Brianna Abbott
Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology's annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.
The project is helping to fill critical gaps in the genetic underpinnings of autism and other neurodevelopmental conditions.
Hospitals across New England are working to help patients navigate the lingering consequences of cancer.
Summer is peak tick season, and with the pests comes the risk of Lyme, spotted fevers and other tick-borne illnesses.
